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Summary A 79-year-old male was treated for 6 months with linezolid for prosthetic knee joint
osteomyelitis. At the end of this 6-month period, quantitative stool cultures revealed partial loss
of the normal gut flora and concomitant colonization by opportunistic pathogens such as
Pseudomonas aeruginosa and other Gram-negatives. Follow-up cultures at 6 weeks after anti-
biotic discontinuation revealed restoration of the normal flora. Prolonged linezolid administra-
tion may lead to replacement of normal gut flora by pathogenic microorganisms, which under
certain conditions might cause systemic infections.
# 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
Linezolid, an oxazolidinone compound, has recently been
introduced for the treatment of serious Gram-positive infec-
tions. The drug has a favorable pharmacokinetic profile and
penetrates the osteo-articular tissue in high concentra-
tions,1,2 with the oral and intravenous administrations being
completely bioequivalent.
While clinical experience regarding the efficacy and
safety of prolonged linezolid treatment of bone and joint
infections is slowly growing3,4 there are no data regarding the
impact of the drug’s prolonged administration on the human
gut flora.* Corresponding author. Tel.: +30 2810 392688;
fax: +30 2810 392359.
E-mail address: kofterid@med.uoc.gr (D.P. Kofteridis).
1201-9712/$36.00 # 2009 International Society for Infectious Diseases.
doi:10.1016/j.ijid.2009.02.001We report herein the case of a patient treated for 6
months with linezolid for prosthetic knee joint osteomyelitis
and present the impact of the regimen on his gut flora.
Case report
A 79-year-old male suffering from diabetes mellitus, hyper-
tension, coronary heart disease, and congestive heart fail-
ure, who had undergone a total knee arthroplasty, presented
2 months after surgery with signs and symptoms of septic
arthritis, with blood and joint fluid cultures positive for
methicillin-resistant Staphylococcus epidermidis. The isolate
was sensitive to macrolides, lincosamides, tetracycline,
chloramphenicol, linezolid, vancomycin, and teicoplanin.
Meanwhile, the patient had a myocardial infarction. Con-
sidering the peri-operative risks as well as the relatively
preserved prosthetic joint’s functionality, any further surgicalPublished by Elsevier Ltd. All rights reserved.
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patient only with debridement and antimicrobials.
He received linezolid at a dose of 600 mg twice daily for 6
months. The drug was well tolerated except in the last
month, when a moderate normocytic anemia (hemoglobin
9.1 g/dl, mean corpuscular volume (MCV) 82.9 fl) was
detected, not responding to combined iron, folate, vitamin
B12 and B6 supplementation. Anemia responded to disconti-
nuation of linezolid, and hemoglobin returned to normal
levels (13.7 g/dl) 1 month later. Neuropathic or retinal toxi-
city was not observed.
As part of his diagnostic work-up the patient underwent
colonoscopy and stool cultures were obtained, while linezolid
treatment was discontinued.
Quantitative stool cultures for bacteria and yeasts
yielded: Pseudomonas aeruginosa (1  108 cfu/ml), Morga-
nella morganii (5  108 cfu/ml), Citrobacter braakii (5 
108 cfu/ml), Escherichia coli (8  109 cfu/ml), Klebsiella
pneumoniae (2  109 cfu/ml), Enterococcus durans
(4  103 cfu/ml), Enterococcus faecalis (2  103 cfu/ml),
Candida albicans (1.3  103 cfu/ml), Bacteroides eggerthii
(2  1011 cfu/ml), Bacteroides ovatus (3  1010 cfu/ml), and
Prevotella buccae (2  1011 cfu/ml). Since the patient did
not complain of diarrhea and no signs of infection were
present, no further therapeutic measures were taken.
Follow-up quantitative stool cultures 6 weeks later
yielded Staphylococcus chromogenes (5  108 cfu/ml),
Micrococcus spp (1  106 cfu/ml), Enterococcus faecium
(1  107 cfu/ml), Enterococcus avium (6  104 cfu/ml), E.
coli (2  108 cfu/ml), C. albicans (2  102 cfu/ml), Fusobac-
terium necrogenes (1  1011cfu/ml), Bacteroides fragilis
(2  1010 cfu/ml), Prevotella buccae (7  1011 cfu/ml), and
Peptostreptococcus prevotii (6  1012 cfu/ml).
Discussion
After 6 months of treatment, linezolid strongly suppressed
our patient’s intestinal Gram-positive anaerobic flora,
although the most important anaerobic Gram-negative bac-
teria, such as Bacteroides and Prevotella spp, were pre-
served. Increased concentrations of Gram-negative
microorganisms such as P. aeruginosa, K. pneumoniae, M.
morganii, E. coli, and C. braakii in the feces were observed,
as well as of C. albicans.
Quantitative stool cultures are performed in order to
investigate alterations in the balance of the intestinal flora,
qualitatively and quantitatively. Results are considered nor-
mal in the absence of changes in the usual intestinal aerobic
and anaerobic flora as it is observed in healthy individuals and
has been described in the literature.5,6
Although the fecal concentration of linezolid is minimal,
the alteration of the gut flora may be attributed to the drug’s
spectrum of activity and its prolonged administration.7 Six
weeks after the discontinuation of linezolid, stool cultures
showed a normal flora with the majority of opportunistic
Gram-negative organisms absent and the concentrations of E.
coli and C. albicans decreased.
Linezolid is a recently introduced oxazolidinone com-
pound for the treatment of serious Gram-positive infections.7
The drug has a favorable pharmacokinetic profile and pene-
trates the osteo-articular tissue in high concentrations,1,2
with the oral and intravenous administrations being comple-tely bioequivalent. The use of linezolid for the treatment of
bone and joint infections, including patients with infected
prostheses, has been described in several case series.8—10
Linezolid has been shown to have high activity against Sta-
phylococcus aureus and S. epidermidis, enterococci, and
streptococci.7,10 Some Gram-negative anaerobes and myco-
bacteria are generally susceptible as well, whereas Enter-
obacteriaceae and other Gram-negative bacteria are
resistant.7,10 From a tolerability point of view, linezolid
shows a favorable safety profile. The most common side
effects include anemia and thrombocytopenia, especially
when linezolid treatment is prolonged, as in bone and joint
infections.11
The human gut is the natural habitat of many bacterial
species. Approximately 99.9% of them are anaerobes, in the
order of 1011 organisms per gram of normal feces. The normal
bacterial microflora, especially the zillion of anaerobes,
prevent colonization of the human gut by pathogenic bac-
teria.5,12 Antimicrobial treatment is the main reason for loss
of the normal flora and its replacement by more pathogenic
microorganisms, such as Pseudomonas, Klebsiella, and Can-
dida spp, as in the present case, or Clostridium and other
species.5 Similar data regarding C. albicans concentration in
the gut after linezolid treatment have been reported in a
mouse model and in humans.13,14 Spread of these organisms
may cause serious systemic infections, especially in immu-
nocompromised hosts, while diarrhea due to alteration of the
normal enteric microflora is common during or after treat-
ment with antimicrobials.5
To our knowledge, this is the first case examining the
impact of prolonged, daily treatment with linezolid on the
human gut flora, showing the replacement of the normal
organisms by Gram-negative pathogens and relatively
increased concentrations of Candida.
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